Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1358.21
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory...
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated...
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3...
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.